Key insights
- Core Scientific's Chief Legal Officer sold $152,523 in stock under a pre-arranged plan. The sale follows a period of significant stock appreciation and comes amid analyst commentary suggesting the stock may be overvalued. The company also secured a $500M credit facility from JPMorgan, adding to a previous $500M facility from Morgan Stanley. Citizens reiterated an outperform rating with a $30 price target, while Canaccord raised its target to $20. The insider selling and high volatility suggest caution.
Todd M. DuChene, Chief Legal and Administrative Officer at Core Scientific, Inc. (NASDAQ:CORZ), sold 10,000 shares of common stock on April 1, 2026, for a total of $152,523. The shares were sold at a weighted average price of $15.2523, with individual sales prices ranging from $14.98 to $15.50.
On March 31, 2026, DuChene also acquired 216,734 shares of Core Scientific common stock with a value of $0, as part of a performance-based restricted stock unit grant. On the same day, 97,652 shares were withheld to cover tax obligations related to the vesting of restricted stock units at a price of $14.96, totaling $1,460,873.
Following these transactions, DuChene directly owns 2,047,089 shares of Core Scientific. The insider sale comes as the stock has delivered a remarkable 127% return over the past year, though InvestingPro analysis suggests the shares are currently overvalued relative to its Fair Value estimate. The stock’s extreme volatility, reflected in its beta of 6.9, is one of several key insights available in the company’s Pro Research Report, which offers comprehensive analysis of Core Scientific alongside 1,400+ other US equities.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
In other recent news, Core Scientific has secured an additional $500 million credit facility from JPMorgan Chase Bank, enhancing its total funded commitments to $1 billion. This follows a prior $500 million loan facility from Morgan Stanley, with both facilities featuring a 364-day term and an interest rate tied to the Secured Overnight Financing Rate plus 250 basis points. Meanwhile, Citizens has reiterated its Market Outperform rating for Core Scientific, maintaining a $30.00 price target, despite revising estimates due to lower near-term contributions from bitcoin mining.
Canaccord has raised its price target for Core Scientific shares from $17 to $20, citing the company’s acquisition of a new site in Texas and increased power capacity at its Dalton, Georgia, and Pecos, Texas locations. Additionally, Needham has upgraded Core Scientific’s stock rating to Buy from Hold, setting a price target of $23.00, based on the stock’s attractive valuation and the anticipation of a new lease agreement in the near future. These developments highlight Core Scientific’s strategic financial maneuvers and expansion efforts amidst evolving market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.